Mirati Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (8)

Latest Posts

About This Stock More About This Stock
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Mirati Therapeutics - Chart Of The Day
Article By: Jim Van Meerten
Monday, March 12, 2018 6:51 PM EDT
Since the Trend Spotter signaled a buy on 1/10 the stock gained 60.69%.
In this article: MRTX
Read
Week In Review: Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business
Article By: ChinaBio® Today
Saturday, January 20, 2018 5:34 PM EDT
Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market.
In this article: JNJ, LLY, CELG, BGNE, MRTX, AMRN
Read
E Small Caps - Long Term Consistent Outperformance
Article By: Tarun Chandra, CFA
Friday, November 10, 2017 6:35 PM EDT
Small cap stocks represent a segment that has consistently outperformed the larger caps over the long term. A portfolio should consider a stable and long-term allocation towards this segment.
In this article: KEM, KRO, WTW, ARNA, OSTK, QQQ, WPRT, DVAX, INSM, IWM, CHGG, ABEO, MRTX, GDS
Read
Citi Doubles Mirati Target, Says 135% Rally 'Not Nearly Enough'
Article By: The Fly
Tuesday, September 19, 2017 8:08 AM EDT
Citi analyst Yigal Nochomovitz now models $300M peak revenue for sitravatinib in NSCLC with inactivating CBL mutations. The analyst keeps a Buy rating on Mirati.
In this article: MRTX
Read

PARTNER HEADLINES

Latest Tweets for $MRTX

No tweets yet!